Core Insights - American Oncology Network (AON) is rapidly expanding and focuses on community-based oncology practices, emphasizing quality initiatives and research collaboration [1][7] - Dr. Taral Patel presented significant research on molecular testing in stage IV non-small cell lung cancer at the IASLC 2025 World Conference on Lung Cancer, highlighting AON's commitment to advancing cancer care [2][3] Company Overview - AON was founded in 2018 and now represents over 300 providers across 20 states, aiming to ensure the long-term success of community oncology through innovative healthcare solutions [7] - The organization promotes health equity by addressing disparities in cancer care and providing comprehensive support to its network physicians [7] Research and Development - Dr. Patel's study, conducted in collaboration with Integra Connect PrecisionQ, aims to improve testing for stage IV lung cancer patients, showcasing AON's focus on quality initiatives [2][4] - The IASLC World Conference is a significant platform for sharing advancements in lung cancer research, attended by a diverse group of stakeholders in the field [3][9] Collaborations and Partnerships - AON collaborates with Integra Connect, a leader in value-based precision medicine, to enhance cancer care through real-world data and analytics [10] - The partnership aims to improve patient outcomes while managing costs and delivering innovations in cancer treatment [10]
Zangmeister Cancer Center Oncologist Dr. Taral Patel Presents Research at IASLC’s World Conference on Lung Cancer in Barcelona